IP Library Granted Patent US 7,456,315
Granted Patent B2
US 7,456,315 · App. 10/787,906 · Granted Nov 25, 2008

Bioavailable diacylhydrazine ligands for modulating the expression of exogenous genes via an ecdysone receptor complex

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,456,315
App. No.
10/787,906
Granted
Nov 25, 2008
Kind
B2
Abstract

The present invention relates to non-steroidal ligands for use in nuclear receptor-based inducible gene expression system, and a method to modulate exogenous gene expression in which an ecdysone receptor complex comprising: a DNA binding domain; a ligand binding domain; a transactivation domain; and a ligand is contacted with a DNA construct comprising: the exogenous gene and a response element; wherein the exogenous gene is under the control of the response element and binding of the DNA binding domain to the response element in the presence of the ligand results in activation or suppression of the gene.

Claims (42)

1. A compound of the general formula:

wherein X and X′ are independently O or S;

A is unsubstituted or substituted phenyl wherein the substituents are independently 1 to 5 H; halo; nitro; cyano; hydroxy; amino (—NR a R b ); alkylaminolkyl (—(CH 2 ) n NR a R b ); (C 1 -C 6 )alkyl; (C 1 -C 6 )haloalkyl; (C 1 -C 6 )cyanoalkyl; (C 1 -C 6 )hydroxyalkyl; (C 1 -C 6 )alkoxy; phenoxy; (C 1 -C 6 )haloalkoxy; (C 1 -C 6 )alkoxy(C 1 -C 6 )alkyl; (C 1 -C 6 )alkenyloxy(C 1 -C 6 )alkyl; (C 1 -C 6 )alkoxy(C 1 -C 6 )alkoxy; (C 1 -C 6 )alkanoyloxy(C 1 -C 6 )alkyl; (C 2 -C 6 )alkenyl optionally substituted with halo, cyano, (C 1 -C 4 )alkyl, or (C 1 -C 4 )alkoxy; (C 2 -C 6 )alkynyl optionally substituted with halo or (C 1 -C 4 )alkyl; formyl; carboxy; (C 1 -C 6 )alkylcarbonyl; (C 1 -C 6 )haloalkylcarbonyl; benzoyl; (C 1 -C 6 )alkoxycarbonyl; (C 1 -C 6 )haloalkoxycarbonyl; (C 1 -C 6 )alkanoyloxy (—OCOR a ); carboxamido (—CONR a R b ); amido (—NR a COR b ); alkoxycarbonylamino (—NR a CO 2 R b ); alkylaminocarbonylamino (—NR a CONR b R c ); mercapto; (C 1 -C 6 )alkylthio; (C 1 -C 6 ) alkylsulfonyl; (C 1 -C 6 )alkylsulfonyl(C 1 -C 6 )alkyl; (C 1 -C 6 )alkylsulfoxido (—S(O)R a ); (C 1 -C 6 )alkylsulfoxido(C 1 -C 6 )alkyl—(CH 2 ) n S(O)R a ); sulfamido (—SO 2 NR a R b ); —SO 3 H; or unsubstituted or substituted phenyl wherein the substituents are independently 1 to 3 halo, nitro, (C 1 -C 6 ) alkoxy, (C 1 -C 6 )alkyl, or amino; or when one or both of two adjacent positions on the phenyl ring are substituted, the attached atoms may form the phenyl-connecting termini of a linkage selected from the group consisting of (—OCH 2 O—), (—OCH(CH 3 )O—), (—OCH 2 CH 2 O—), (—OCH(CH 3 )CH 2 O—), (—S—CH═N—), (—CH 2 OCH 2 O—), (—O(CH 2 ) 3 —), (═N—O—N═), (—C═CH—NH—), (—OCF 2 O—), (—N—CH═N—), (—CH 2 CH 2 O—), and (—(CH 2 ) 4 —);

B is

(a) unsubstituted or substituted phenyl wherein the substituents are independently 1 to 5 H; halo; nitro; cyano; hydroxy; amino (—NR a R b ); alkylaminolkyl (—(CH 2 ) n NR a R b ); (C 1 -C 6 )alkyl; (C 1 -C 6 )haloalkyl; (C 1 -C 6 )cyanoalkyl; (C 1 -C 6 )hydroxyalkyl; (C 1 -C 6 )alkoxy; phenoxy; (C 1 -C 6 )haloalkoxy; (C 1 -C 6 )alkoxy(C 1 -C 6 )alkyl; (C 1 -C 6 )alkenyloxy(C 1 -C 6 )alkyl; (C 1 -C 6 )alkoxy(C 1 -C 6 )alkoxy; (C 1 -C 6 )alkanoyloxy(C 1 -C 6 )alkyl; (C 2 -C 6 )alkenyl optionally substituted with halo, cyano, (C 1 -C 4 ) alkyl, or (C 1 -C 4 )alkoxy; (C 2 -C 6 )alkynyl optionally substituted with halo or (C 1 -C 4 )alkyl; formyl; carboxy; (C 1 -C 6 )alkylcarbonyl; (C 1 -C 6 )haloalkylcarbonyl; benzoyl; (C 1 -C 6 )alkoxycarbonyl; (C 1 -C 6 )haloalkoxycarbonyl; (C 1 -C 6 )alkanoyloxy (—OCOR a ); carboxamido (—CONR a R b ); amido (—NR a COR b ); alkoxycarbonylamino (—NR a CO 2 R b ); alkylaminocarbonylamino (—NR a CONR b R c ); mercapto; (C 1 -C 6 )alkylthio; (C 1 -C 6 ) alkylsulfonyl; (C 1 -C 6 )alkylsulfonyl(C 1 -C 6 )alkyl; (C 1 -C 6 )alkylsulfoxido (—S(O)R a ); (C 1 -C 6 )alkylsulfoxido(C 1 -C 6 )alkyl (—CH 2 ) n S(O)R a ); sulfamido (—SO 2 NR a R b ); —SO 3 H; or unsubstituted or substituted phenyl wherein the substituents are independently 1 to 3 halo, nitro, (C 1 -C 6 ) alkoxy, (C 1 -C 6 )alkyl, or amino; or when one or both of two adjacent positions on the phenyl ring are substituted, the attached atoms may form the phenyl-connecting termini of a linkage selected from the group consisting of (—OCH 2 O—), (—OCH(CH 3 )O—), (—OCH 2 CH 2 O—), (—OCH(CH 3 )CH 2 O—), (—S—CH═N—), (—CH 2 OCH 2 O—), (—O(CH 2 ) 3 —), (═N—O—N═), (—C═CH—NH—), (—OCF 2 O—), (—NH—CH═N—), (—CH 2 CH 2 O—), (—(CH 2 ) 4 —), —C═N—NHC(O)NR a R b , and —C═N—NHC(O)C(O)NR a R b ;

(b) unsubstituted 6-membered heterocycle or substituted 6-membered heterocycle having 1-3 nitrogen atoms and 3-5 nuclear carbon atoms where the substituents are from one to three of the same or different halo; nitro; hydroxy; (C 1 -C 6 )alkyl; (C 1 -C 6 )alkoxy; (C 1 -C 6 )thioalkoxy; carboxy; (C 1 -C 6 )alkoxycarbonyl; (C 1 -C 6 )carboxyalkyl; (C 1 -C 6 )alkoxycarbonylalkyl having independently the stated number of carbon atoms in each alkyl group; —CONR a R b ; amino; (C 1 -C 6 )alkylamino; (C 1 -C 6 )dialkylamino having independently the stated number of carbon atoms in each alkyl group; haloalkyl; —C═N—NHC(O)NR a R b ; or —C═N—NHC(O)C(O)NR a R b ; or

(c) 5-benzimidazolyl; 1-trityl-5-benzimidazolyl; 3-trityl-5-benzimidazolyl; 1H-indazole-3-yl; 1-trityl-1H-indazole-3-yl; or 1-(C 1 -C 6 )alkyl-1H-indole-2-yl;

E is unsubstituted or substituted (C 4 -C 10 ) branched alkyl wherein the substituents are independently 1-4 cyano; halo; (C 5 -C 6 )cycloalkyl; phenyl; (C 2 -C 3 )alkenyl; hydroxy, (C 1 -C 6 )alkoxy; carboxy; (C 1 -C 6 )alkoxycarbonyl; (C 1 -C 6 )alkanoyloxy (—OCOR a ); formyl; (C 1 -C 6 )trialkylsilyloxy having independently the stated number of carbon atoms in each alkyl group; —C═N—OR a ; —C═N—R d ; —C═N—NHC(O)NR a R b ; or —C═N—NHC(O)C(O)NR a R b ;

wherein R a , R b , and R c are independently H, (C 1 -C 6 )alkyl, or phenyl; R d is hydroxy(C 1 -C 6 )alkyl; and n=1-4; and

G is H or CN;

provided that:

1) when E is unsubstituted or substituted (C 4 -C 10 ) branched alkyl wherein the substituents are independently 1-4 cyano; halo; (C 2 -C 3 )alkenyl; carboxy; or (C 1 -C 6 )alkoxycarbonyl;

then B is

(a) substituted phenyl which bears at least one —C═N—NHC(O)NR a R b or —C═N—NHC(O)C(O)NR a R b group;

(b) substituted 6-membered heterocycle having 1-3 nitrogen atoms and 3-5 nuclear carbon atoms which bears at least one haloalkyl group; or

(c) 5-benzimidazolyl; 1-trityl-5-benzimidazolyl; 3-trityl-5-benzimidazolyl; 1H-indazole-3-yl; 1-trityl-1H-indazole-3-yl; or 1-(C 1 -C 6 )alkyl-1H-indole-2-yl;

wherein R a , R b are independently H, (C 1 -C 6 )alkyl, or phenyl; or

2) when E is a substituted (C 4 -C 10 ) branched alkyl which bears at least one of phenyl; hydroxy, (C 1 -C 6 )alkoxy; or formyl;

then B is

(a) substituted phenyl which bears at least one —C═N—NHC(O)NR a R b or —C═N—NHC(O)C(O)NR a R b group;

(b) substituted or unsubstituted 6-membered heterocycle having 1-3 nitrogen atoms and 3-5 nuclear carbon atoms; or

(c) 5-benzimidazolyl; 1-trityl-5-benzimidazolyl; 3-trityl-5-benzimidazolyl; 1H-indazole-3-yl; 1-trityl-1H-indazole-3-yl; or 1-(C 1 -C 6 )alkyl-1H-indole-2-yl;

wherein R a and R b are independently H, (C 1 -C 6 )alkyl, or phenyl.

2. The compound of claim 1 wherein X and X′ are O and G is H.

3. The compound of claim 2 wherein the compound is selected from the group consisting of:

3,5-Dimethyl-benzoic acid N′-(2-ethyl-3-methoxy-benzoyl)-N-(2-hydroxyimino-1,1-dimethyl-ethyl)-hydrazide;

Acetic acid 2-[N-(3,5-dimethyl-benzoyl)-N′-(2-ethyl-3-methoxy-benzoyl)-hydrazino]-2-methyl-propyl ester;

2-Ethyl-3-methoxy-benzoic acid N′-tert-butyl-N′-(1-methyl-1H-indole-2-carbonyl)-hydrazide;

3-(H 2 NC(O)NHN═CH-5-methyl-benzoic acid N-tert-butyl-N′-(2-ethyl-3-methoxy-benzoyl)-hydrazide;

3-(H 2 NC(O)C(O)NHN═CH-5-methyl-benzoic acid N-tert-butyl-N′-(2-ethyl-3-methoxy-benzoyl)-hydrazide;

2-Methoxy-6-trifluoromethyl-nicotinic acid N-tert-butyl-N′-(3-methoxy-2-methyl-benzoyl)-hydrazide;

3-Methoxy-2-methyl-benzoic acid N′-tert-butyl-N′-(1-methyl-2-oxo-6-trifluoromethyl-1,2-dihydro-pyridine-3-carbonyl)-hydrazide;

2-Methoxy-nicotinic acid N-(2,2-dimethyl-1-phenyl-propyl)-N′-(4-ethyl-benzoyl)-hydrazide;

1H-Benzoimidazole-5-carboxylic acid, N-tert-butyl-N′-(2-ethyl-3-methoxy-benzoyl)-hydrazide;

1-(or 3-)Trityl-1H-benzoimidazole-5-carboxylic acid N-tert-butyl-N′-(2-ethyl-3-methoxy-benzoyl)-hydrazide;

1H-Indazole-3-carboxylic acid N-tert-butyl-N′-(2-ethyl-3-methoxy-benzoyl)-hydrazide;

1-Trityl-1H-indazole-3-carboxylic acid N-tert-butyl-N′-(2-ethyl-3-methoxy-benzoyl)-hydrazide;

3,5-Dimethyl-benzoic acid N-[2-(tert-butyl-dimethyl-silanyloxy)-1,1-dimethyl-ethyl]-N′-(2-ethyl-3-methoxy-benzoyl)-hydrazide;

3,5-Dimethyl-benzoic acid N′-(2-ethyl-3-methoxy-benzoyl)-N-[2-(2-hydroxy-ethylimino)-1,1-dimethyl-ethyl]-hydrazide;

3,5-Dimethyl-benzoic acid N-[(H 2 NC(O)NHN—C)(CH3) 2 C—]—N′-(2-ethyl-3-methoxy-benzoyl)-hydrazide; and

3,5-Dimethyl-benzoic acid N-[(H 2 NC(O)C(O)NHN═C)(CH3) 2 C—]—N′-(2-ethyl-3-methoxy-benzoyl)-hydrazide.

4. The compound of claim 1 wherein said haloalkyl is —CF3.

Assignments (10)
MERGER Recorded May 6, 2013
From: NEW RHEOGENE I, LLC; NEW RHEOGENE II, LLC
To: RHEOGENE, INC.
Reel/Frame 030356/0685 →
MERGER Recorded Aug 7, 2008
From: RHEOGENE HOLDINGS, INC.
To: RHEOGENE, INC. (DE CORPORATION)
Reel/Frame 021356/0581 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 13, 2007
From: RGH LLC
To: NEW RHEOGENE I LLC
Reel/Frame 019157/0310 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 13, 2007
From: ROHM AND HAAS COMPANY
To: RGH LLC
Reel/Frame 019155/0964 →
MERGER Recorded Apr 12, 2007
From: RHEOGENE, INC. (A DELAWARE CORPORATION)
To: INTREXON CORPORATION
Reel/Frame 019150/0044 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 12, 2007
From: HORMANN, ROBERT E; POTTER, DAVID W; TICE, COLIN M; CARLSON, GLENN R; MEYER, ANDREW L; OPIE, THOMAS R; CHORTYK, ORESTES
To: ROHM AND HAAS COMPANY
Reel/Frame 019152/0885 →
MERGER Recorded Apr 11, 2007
From: RHEOGENE, INC.
To: RHEOGENE, INC. (A DELAWARE CORPORATION)
Reel/Frame 019144/0317 →
LICENSE Recorded Apr 10, 2007
From: RHEOGENE HOLDINGS, INC.
To: RHEOGENE, INC.
Reel/Frame 019141/0920 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 10, 2007
From: UNIVERISTY OF PITTSBURGH MEDICAL CENTER
To: RHEOGENE HOLDINGS, INC.
Reel/Frame 019138/0729 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 9, 2007
From: NEW RHEOGENE I, LLC
To: UNIVERSITY OF PITTSBURGH MEDICAL CENTER
Reel/Frame 019132/0925 →